'/%3E%3C/svg%3E%0A){kind=small}
2024
Bajaj PS, LaGasse K, Rizio AA, Huynh G, McCausland KL, Conrad A, Sprinz KI.
Clin Lymphoma Myeloma Leuk.2024;24(Suppl 2):S101.
Palladini G, Liedtke M, Zago W, Dolan P, Kinney GG, Gertz MA.
Leuk Lymphoma. 2024;65(8):1068-1078.
Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial.
D’Souza A, Sanchorawala V, Kastritis E, Wechalekar A, Schönland S, Comenzo R, Sprinz KI, Nie C, Lin T, Gertz MA.
Presented at the XIX International Symposium on Amyloidosis 2024; May 26 30, 2024. Rochester, MN.
Increasing Prevalence and Incidence of AL Amyloidosis Among Older Adults in the US.
Bajaj P, Broder MS, Das AK, Chang E, Tarbox MH, Conrad A, D’Souza A.
Amyloid. 2024;31(sup1):S30-S31 [abstract #87].
2023
Sanchorawala V, Wechalekar AD, Kastritis E, Palladini G, Schönland S, Comenzo R, D’Souza A, Khouri J, Jimenez-Zepeda V, Sprinz KI, Hao H, Huang W, Aubrey LG, Gertz MA.
Blood. 2023;142(Suppl 1):3409.
Determinants of Higher Cost and Inpatient Hospitalization Among Patients With AL Amyloidosis.
D’Souza A, Broder MS, Das AK, Chang E, Quock T, Conrad A, Tarbox MH, Bajaj P.
Value in Health. 2023;26(12 Suppl):S127.
D’Souza A, Broder MS, Das AK, Chang E, Quock TP, Sprinz I, Conrad A, Tarbox MH.
J Manag Care Spec Pharm. 2023;29(10-a Suppl):S53.
Rizio AA, McCausland KL, Carty MK, Conrad A, Quock TP.
Patient Rel Outcome Meas. 2023;14:297-304.
Gertz MA, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock T, Rosenbaum C, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, Broder MS.
Clinicoecon Outcomes Res. 2023;15:673-680.
Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau H, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G.
Blood. 2023;142(14):1208-1218.
Rizio AA, White MK, D’Souza A, Hsu K, Schmitt P, Quock TP, Signorovitch J, Lousada I, Sanchorawala V.
Patient Relat Outcome Meas. 2023;14:153-169.
Quock TP, D’Souza A, Broder MS, Bognar K, Chang E, Tarbox MH.
J Comp Eff Res. 2023;12(2):e220185.
2022
D’Souza A, Broder MS, Bognar K, Chang E, Tarbox MH, Quock TP.
J Comp Eff Res. 2022;11(17):1225-1230.
Gertz MA, Jin Y, Conrad A, Nie C.
Blood. 2022;140(Suppl 1):1839-1840.
Healthcare Utilization Among Patients With Advanced Systemic Light Chain Amyloidosis.
Gertz MA, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock TP, Rosenbaum CA, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, Broder MS.
Blood. 2022;140(Suppl 1):13129-13131.
Birtamimab in Patients With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory AFFIRM-AL Phase 3 Study.
Gertz MA, Sanchorawala V, Wechalekar A, Ando Y, Koh Y, Nie C, Jin Y, Conrad A, Kastritis E, On Behalf of the AFFIRM-AL Study Investigators.
Presented at International Society on Amyloidosis; September 4-8, 2022; Heidelberg, Germany.
Diagnostic Hospitalization and Associated Costs in Patients With Amyloid Light-Chain Amyloidosis.
Quock TP, Chang E, Bognar K, Tarbox MH, D’Souza A, Broder MS.
Presented at International Society on Amyloidosis; September 4-8, 2022. Heidelberg, DE.
2021
Gertz MA, Tripuraneni R, Kinney GG.
Blood. 2021;138(Suppl 1):2754.
Work Outcomes Among Patients With Light Chain (AL) Amyloidosis: Findings From Three Patient Cohorts.
Rizio AA, McCausland KL, White MK, Quock TP.
Patient Relat Outcome Meas. 2021;12:339-347.
Pre-2020
Gertz MA, Cohen AD, Comenzo, RL, Du Mond C, Kastritis E, Landau H, Libby EN, Liedtke M, Merlini G, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Kinney GG.
Blood. 2019;134(Suppl 1):3166.
Quock TP, Yan T, Tieu R, D’Souza A, Broder MS.
Clinicoecon Outcomes Res. 2019;11:431-439.
Cardiac biomarkers and health‐related quality of life in patients with light chain (AL) amyloidosis.
McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie S, Sanchorawala V.
Brit J Haematol. 2019;185(5):998-1001.
Quock TP, Yan T, Chang E, Guthrie S, Broder MS.
J Comp Eff Res. 2018;7(6):549-559.
Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data.
Quock TP, Yan T, Chang E, Guthrie S, Broder MS.
Blood Adv. 2018;2(10):1046-1053.
Light Chain (AL) Amyloidosis: The Journey to Diagnosis.
McCausland KL, White MK, Guthrie S, Quock TP, Finkel M, Lousada I, Bayliss MS.
Patient. 2018;11(2):207-216.
Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie S, Liedtke M.
J Clin Oncol. 2016;34(10):1097-1103.
Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, Salmans JR, Barbour RM, Shughrue PJ, Nijjar T, Schenk D, Kinney GG, Wagner Zago W.
Amyloid. 2016;23(3):168-177.
AL Amyloid Imaging and Therapy With a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils.
Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D.
PLoS One. 2012;7(12):e52686.
Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies.
Wall JS, Kennel SJ, Richey T, Allen A, Stuckey A, Weiss DT, Macy S, Barbour R, Seubert P, Solomon A, Schenk D.
Front Immunol. 2011;2:32.
Includes publications related to wholly owned assets and select publications related to partnered assets.
2024
Increasing Representation and Diversity in Clinical Trials of Alzheimer’s Disease: Recruitment of Ethnically Diverse Participants With Alzheimer’s Disease in the Phase 1 ASCENT Clinical Trials of PRX012.
Swanson C, Martényi F, Tooker RE, Masterman D, Fitzgerald C, Johnson A, Li L, Quinceno ME, Kinney GG, Garren H.
Presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024; October 29-November 1, 2024; Madrid, Spain and virtual.
Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer’s Disease: A Quantitative Survey.
Silber A, Athavale A, O’Hara M, Masterman D, Bajaj PS.
Presented at 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024; October 29-November 1, 2024; Madrid, Spain and virtual.
Phase 1 Single and Multiple Dose Clinical Trials (ASCENT-1 and ASCENT-2) for Dose-Finding of PRX012 in Participants With Biologically Confirmed Alzheimer’s Disease.
Swanson C, Martényi F, Tooker RE, Campbell BM, Johnson A, Li L, Quinceno ME, Zago WM, Kinney GG, Garren H.
Presented at the Alzheimer’s Association International Conference® (AAIC) 2024; July 28 August 1, 2024; Philadelphia, PA, USA and virtual.
Silber A, Athavale A, Kulkarni A, O’Hara M, Mattke S, Bajaj PS.
Value Health. 2024;27(6):S229.
2023
Tourino C, Trumble A, Louie L, Barbour RM, Kinney GG, Campbell BM, Zago W.
Alzheimers Dement. 2023;19(S24):e082687.
Martényi F, Campbell BM, Kinney GG, Lee J, Jin Y, Zago WM, Garren H.
Alzheimers Dement. 2023;19(S21):e074181. Partnership with BMS.
Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ.
Campbell BM, Zhang G, Salmans J, Elmaarouf A, Tam S, Porat A, Skov M, Dolan PJ, Kinney GG, Zago WM.
Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2023; March 28-April 1, 2023; Gothenburg, Sweden and virtual.
2021
Tam S, Zhang G, Li L, Elmaarouf A, Salmans J, Skov M, Dolan P, Kinney GG, Campbell B, Zago WM.
Alzheimers Dement. 2021;17(S9):e057773.
Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression Via Blockade on Neuronal Internalization.
Dolan PJ, Tam SJ, Nijjar T, Holden MR, Tourino C, Elmaarouf A, Thomas K, Li L, Prill H, Bard F, Zago W.
Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2021; March 9-14, 2021; virtual. Partnership with BMS
2020
Skov M, Barbour R, Dolan P, Elmaarouf A, Goldbach E, Holden M, Li L, Nijjar T, Prill H, Salmans J, Tam S, Thomas K, Tourino C, Bard F, Kinney GG, Zago W.
J Prev Alz Dis. 2020;7(S1):S105.
Development of a Dual Aβ/Tau Vaccine for the Prevention and Treatment of Alzheimer’s Disease.
Barbour R, Elmaarouf A, Prill H, Thomas K, Bard F, Kinney G, Zago W.
J Prev Alz Dis. 2020;7(S1):S104-105.
Pre-2020
Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.
Alzheimers Dement. 2013;9(5 Suppl):S105-115.
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific.
Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.
J Neurosci. 2012;32(8):2696-2702.
Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T.
Exp Neurol. 2012;238(1):38‑43.
Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI.
J Biol Chem. 2010;285(5):3417-3427.
Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal Antibodies.
Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P.
Ann Neurol. 2005;58(3):430-435.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.
Nat Med. 2000;6(8):916-919.
Immunization With Amyloid-Beta Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.
Nature. 1999;400(6740):173-177.
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J.
Nature. 1995;373(6514):523-527.
Amyloid Beta-Peptide Is Produced by Cultured Cells During Normal Metabolism.
Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ.
Nature. 1992;359(6393):322-325.
Includes publications related to wholly owned assets and select publications related to partnered assets.
2024
Suhr OB, Grogan M, Martins da Silva A, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG.
Amyloid. 2024 Oct 29:1-8. Partnership with Novo Nordisk.
Prasinezumab Slows Motor Progression in Rapidly Progressing Early-Stage Parkinson’s Disease.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A, PASADENA Investigators, Prasinezumab Study Group.
Nat Med. 2024;30(4):1096-1103. Partnership with Roche.
2022
Trial of Prasinezumab in Early-Stage Parkinson’s Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay J-P, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D’Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga S, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A, PASADENA Investigators, Prasinezumab Study Group.
N Engl J Med. 2022;387(5):421-432. Partnership with Roche.
Development of C-Terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies.
Barbour R, Elmaarouf A, Holden M, Louie L, Prill H, Skov M, Tam S, Tourino C, Campbell B, Kinney GG, Zago W.
Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2022; March 15-20, 2022; Barcelona, Spain and virtual.
2021
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; and PASADENA Investigators and Prasinezumab Study Group.
Front Neurol. 2021;12:705407. Partnership with Roche.
Pre-2020
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.
JAMA Neurol. 2018;75(10):1206-14. Partnership with Roche.
First-in-Human Assessment of PRX002, an Anti-α-Synuclein Monoclonal Antibody, in Healthy Volunteers.
Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG.
Mov Disord. 2017;32(2):211-218. Partnership with Roche.
Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin
Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, Torres R, Tapia JR, Salmans J, Barbour R, Tam SJ, Flanagan K, Zago W, Kinney GG.
Amyloid. 2016 Jun;23(2):86-97.
The purpose of this resource is to provide information to US healthcare professionals (HCPs) about Prothena’s investigational drug candidates.
This resource contains medical and scientific information related to Prothena’s products and/or uses that have not been approved by any regulatory authority (e.g., FDA, EMA).
If you are a patient or caregiver, please discuss any medical or treatment questions with your healthcare provider.
All Prothena drugs (wholly-owned or partnered) referenced herein are investigational drugs and not approved by any regulatory authority.
